Nimesil treatment of gouty arthritis


Cite item

Full Text

Abstract

Aim. To evaluate efficacy and safety ofnimesil, a selective inhibitor of cyclooxigenase-2, in gouty arthritis (GA).
Material and methods. Nimesil was given to 20 male patients with GA (mean age 53.8 years, mean duration of the disease 8.1 years) in a dose 100 mg twice a day for 14 or 21 days depending on positive clinical changes (13 and 6patients, respectively). The articular swelling index, supraarticular skin hyperemia, the articular index, pain in rest and movement were estimated on the treatment day 1, 5, 14 and 21. Arterial pressure was controlled in all the patients. ESR, uric acid, seromucoid, ALT, AST, gamma-GTP, glucose levels were measured before and after the treatment. Results. Nimesil relieved pain and inflammation (ESR and seromucoid level lowered significantly). Effects on the other estimates were not registered. One patient developed generalized urticaria on the treatment day 5. The drug was discontinued in him.
Conclusion. Nimesil can be used as monotherapy of an acute attack of gout. In a dose 200 mg/day nimesil provides an effective and fast treatment of gout, is well tolerated and safe.

References

  1. Fam A. G. Managing problem gout. Ann. Acad. Med. Singapore. 1998; 27(1): 93-99.
  2. Hollander J. L. Intra-articular hydrocortisone in arthritis and allied conditions. J. Bone Jt Surg. 1953; 35A: 983-990.
  3. Hart F. D., Boardman P. L. Indomethacin: A new non-steroid anti-inflammatory agent. Br. Med. J. 1963; 2: 956-970.
  4. Norcross В. М. Treatment of connective tissue diseases with a new nonsteroidal compound (indomethacin). Arthr. and Rheum. 1963; 6: 290.
  5. Smuth C. J., Percy J. S. Comparison of indomethacin and fenylbutazone in acute gout. Ann. Rheum. Dis. 1973. 32: 351- 353.
  6. Altman R. D., Honig S., Levin J. M., Lightfoot R. W. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J. Rheumatol. 1988; 15: 1422-1326.
  7. Axelrod D., Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin im the treatment of acute gout. Arthr. and Rheum. 1988; 31: 803-805.
  8. Lomen P. L., Turner L. F., Lamborn K. R. et al. Flurbiprofen in the treatment of acute gout: a comparison with indomethacin. Am. J. Med. 1986; 80: 134-139.
  9. Ruotsi A., Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin. Scand. J. Rheumatol. 1978; 21: 15-17.
  10. Schumacher H. R., Boice J. A., Daikh D. K. et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. Br. Med. J. 2002; 324(7352): 1488-1492.
  11. Singh G., Rosen-Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. J. Rheumatol, 1998; 51: 8-16.
  12. Thompson M., Percy J. S. Further experience with indomethacin in the treatment of rheumatic disorders. Br. Med. J. 1966; 1:80-83.
  13. Wallace S. L., Robinson H., Masi A. T. et al. Pleliminary criteria for the classification of the acute arthritis of the preliminary gout. Arthr. and Rheum. 1977; 20(3): 895-900.
  14. Segasothy M., Clin G. I., Sia К. К. et al. Chronic nephrotoxicity of antiinflammatory drugs used in the treatment of arthritis. Br. J. Rheumatol. 1995; 34: 162-165.
  15. Henry D., Page J., Whyte I. et al. Comsumption of non-steroidal antiinflammatory drugs and the development of functional renal impairment in elderly subjects: Results of a case control study. Br. J. Clin. Pharmacol. 1997; 44: 85-90.
  16. Tarng D. C., Lin H. Y., Shyong M. L. et al. Renal function in gout patients. Am. J. Nephrol. 1995; 15: 31-37.
  17. Unsworthy J., Sturman S., Lunec J., Blake D. R. Renal impairment associated with non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 1987; 46: 233-236.
  18. Sandler D. P., Smith J. C., Weinberg С. R. et al. Analgesic use and chronic renal disease. N. Engl. J. Med. 1989; 320: 1238- 1243.
  19. Benetl W. M., Debroe M. E. Analgesic nephropathy - a preventable renai disease. Ibid. 1269-1271.
  20. Perez-Ruiz F., Calabozo M., Herrero-Beites A. M. et al. Improvement of renal function on patients with chronic gout after prover control of hyperuricemia and gouty bouts. Nephron 2000; 86: 287-291.
  21. Faires J. S., McCarty D. J. Acute arthritis in man and dog after synovial injection of sodium urate crystals. Lancet 1962; 2: 682.
  22. Seegmiller J. E., Howell R. R., Malawista S. E. The inflammatory reaction to sodium urate. J. A. M. A. 1972; 180: 125.
  23. Gordon T. P., Terkeltaub R. A., Ginsberg M. H. Gout: Crystalinduced inflammation. In: Gallin J. L., Goldstein I. M., Snyderman R., eds.Inflammation: Basic principles and clinical correlates. New York: Raven; 1988. 775.
  24. Terkeltaub R. A., Zachariae C., Santoro D. et al. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystalinduced inflammation. Arthr. and Rheum. 1991: 34: 894.
  25. Guerne P. A., Terkeltaub R. A., Zuraw В., Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Ibid. 1989; 32: 1443.
  26. Di Giovine F. S., Malawista S. E., Thorton E., Duff G. W. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial ceils. J. Clin. Invest. 1991; 78: 1375.
  27. Woolfs A. D., Dieppe P. A. Mediators of crystal-induced inflammation in the joint. Br. Med. Bull. 1987; 43: 429.
  28. Terkeltaub R. A. Pathogenesis and treatment of crystal-induced inflammation. In: McCarty D. J., Koopman W. J., eds. Arthritis and allied conditions. London: Lea & Febiger: 1993; 1819.
  29. Smith W. L., Borgeat P., Fitzpatrick F. A. The eiscosanoids: cycloxygenase, lipoxygenase and epoxygenase pathway. In: Vance D. E., Vance J., eds. Biochemistry of lipids, lipoproteins and membranes. New York: Elsevier; 1991. 297.
  30. Vane J. R., Batting R. M. Mechanism of action of anti-inflammatory drugs. Scand. J. Rheumatol. 1996; 102: 9.
  31. Hershmann H. R. Prostaglandin syntase 2. Biochim. Biophys. Acta 1996; 1299: 125.
  32. Pouliot M., James M. J., McColl S. R. et al. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998; 91(5): 1769-1776.
  33. WHO/NCD/NCM/CRA/99.1. Low Back Pain Initiative: 109-113.
  34. Koh W. H., Seah A., Chai P. Clinical presentation and disease associations in gout: a hospital-based study of 100 patients in Singapore. Ann. Acad. Med. Singapore 1998; 27: 7-10.
  35. Gutman A. B. Views on the pathogenesis and management of primary gout. 1971. J. Bone Jt Surg. 1972; 54A: 357-372.
  36. De Lecuw P. W. Nonsteroidal anti-inflammatory drugs and hypertension. The risk and perspective. Drugs 1996; 51(2): 179- 187.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies